Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.14850
Abstract: AIM To evaluate pharmacokinetic equivalence and preliminary safety of the adalimumab biosimilar CT-P17 administered via autoinjector (CT-P17 AI) or prefilled syringe (CT-P17 PFS) in healthy subjects. METHODS This phase I, open-label study (ClinicalTrials.gov: NCT04295356) randomised… read more here.
Keywords: p17 pfs; equivalence; p17 p17; pharmacokinetic equivalence ... See more keywords